Cardiovascular Systems Inc (NASDAQ:CSII) Receives $44.00 Consensus Target Price from Analysts

Share on StockTwits

Cardiovascular Systems Inc (NASDAQ:CSII) has been assigned an average rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $44.00.

Several research analysts have weighed in on CSII shares. BidaskClub lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 26th. Needham & Company LLC increased their target price on shares of Alteryx to $108.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Bank of America set a $7.00 target price on shares of Deutsche Bank and gave the stock a “sell” rating in a research note on Thursday, April 11th. Finally, Zacks Investment Research lowered shares of Genprex from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th.

CSII stock traded down $0.35 during mid-day trading on Tuesday, hitting $44.13. 224,617 shares of the company were exchanged, compared to its average volume of 269,344. The company has a quick ratio of 3.78, a current ratio of 4.25 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 882.60 and a beta of 1.81. The firm’s fifty day simple moving average is $41.33. Cardiovascular Systems has a 12-month low of $24.84 and a 12-month high of $45.61.

Cardiovascular Systems (NASDAQ:CSII) last announced its earnings results on Wednesday, May 1st. The medical device company reported $0.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The company had revenue of $63.31 million during the quarter, compared to analyst estimates of $62.80 million. Cardiovascular Systems had a net margin of 0.84% and a return on equity of 1.47%. As a group, equities analysts expect that Cardiovascular Systems will post -0.01 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Cardiovascular Systems by 12.5% during the fourth quarter. BlackRock Inc. now owns 2,901,471 shares of the medical device company’s stock worth $82,663,000 after purchasing an additional 322,994 shares in the last quarter. Partner Fund Management L.P. raised its holdings in Cardiovascular Systems by 57.2% in the fourth quarter. Partner Fund Management L.P. now owns 1,599,867 shares of the medical device company’s stock valued at $45,580,000 after acquiring an additional 581,950 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in Cardiovascular Systems by 1.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 836,593 shares of the medical device company’s stock valued at $23,834,000 after acquiring an additional 12,645 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Cardiovascular Systems by 2.1% in the first quarter. New York State Common Retirement Fund now owns 535,047 shares of the medical device company’s stock valued at $20,685,000 after acquiring an additional 10,900 shares in the last quarter. Finally, Norges Bank acquired a new stake in Cardiovascular Systems in the fourth quarter valued at approximately $14,258,000. 92.06% of the stock is currently owned by institutional investors and hedge funds.

About Cardiovascular Systems

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Recommended Story: What are the advantages to having securities held in street name?

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.